Biopharmaceutical CMO and CRO

Global Biopharmaceutical CMO and CRO Market to Reach US$45.9 Billion by 2030

The global market for Biopharmaceutical CMO and CRO estimated at US$35.1 Billion in the year 2024, is expected to reach US$45.9 Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2024-2030. Biologics Type, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$32.1 Billion by the end of the analysis period. Growth in the Biosimilars Type segment is estimated at 3.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$9.6 Billion While China is Forecast to Grow at 8.4% CAGR

The Biopharmaceutical CMO and CRO market in the U.S. is estimated at US$9.6 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$9.6 Billion by the year 2030 trailing a CAGR of 8.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.8% and 3.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.7% CAGR.

Global Biopharmaceutical CMO and CRO Market - Key Trends & Drivers Summarized

Why Is Outsourcing Becoming Critical in Biopharmaceutical Development?

The increasing complexity of biopharmaceutical development has made outsourcing to Contract Manufacturing Organizations (CMOs) and Contract Research Organizations (CROs) an essential strategy for pharmaceutical companies worldwide. With biologics and biosimilars driving innovation in the healthcare sector, the demand for specialized expertise, infrastructure, and regulatory compliance capabilities is surging. CMOs and CROs offer scalable, cost-efficient, and technologically advanced solutions that enable pharmaceutical firms to expedite research, clinical trials, and production while maintaining quality standards. The rise of personalized medicine, coupled with stringent regulatory requirements, has further cemented the role of outsourcing in biopharmaceutical development. Additionally, the COVID-19 pandemic underscored the importance of agile and flexible manufacturing capabilities, prompting increased reliance on external contract service providers for vaccine and monoclonal antibody production. As companies continue to streamline operations and focus on core competencies, the role of CMOs and CROs in accelerating drug development timelines and reducing operational costs is becoming more pronounced.

How Are Technological Advancements Reshaping the CMO and CRO Landscape?

The adoption of cutting-edge technologies such as artificial intelligence (AI), machine learning, and automation is revolutionizing the biopharmaceutical CMO and CRO market. AI-powered predictive analytics and advanced bioinformatics are improving drug discovery, patient recruitment, and clinical trial efficiency. Robotics and continuous manufacturing techniques are enhancing the scalability and precision of biopharmaceutical production, reducing waste and operational bottlenecks. Furthermore, advancements in cell and gene therapy manufacturing have necessitated the need for specialized contract service providers equipped with state-of-the-art bioprocessing technologies. As the industry moves towards more complex biologics, including monoclonal antibodies, vaccines, and gene-modified therapies, CMOs and CROs are expanding their capabilities to include modular production facilities, single-use bioreactors, and digital twin technology for process optimization. This wave of innovation is not only increasing efficiency but also ensuring better compliance with evolving regulatory frameworks, thereby accelerating the commercialization of next-generation biopharmaceuticals.

What Market Trends Are Driving the Growth of Biopharmaceutical CMO and CRO Services?

Several macroeconomic and industry-specific trends are fueling the growth of the biopharmaceutical CMO and CRO market. The rising prevalence of chronic diseases such as cancer, cardiovascular disorders, and autoimmune conditions has escalated the demand for biologics, propelling pharmaceutical firms to outsource development and production. Additionally, the globalization of clinical trials has led to a surge in demand for CROs that can navigate complex regulatory landscapes across multiple regions. Emerging markets in Asia-Pacific, particularly China and India, are becoming key hubs for biopharmaceutical outsourcing due to cost advantages, skilled labor, and government incentives. Another significant trend is the consolidation within the CMO and CRO sectors, as larger players acquire smaller firms to expand their service portfolios and geographic reach. Furthermore, the increasing focus on sustainability and green chemistry is influencing contract manufacturers to adopt eco-friendly production processes, minimizing waste generation and energy consumption in biopharmaceutical production. The convergence of these factors is solidifying the role of contract service providers as indispensable partners in the pharmaceutical value chain.

What Are the Key Drivers Fueling the Growth of the Biopharmaceutical CMO and CRO Market?

The growth in the biopharmaceutical CMO and CRO market is driven by several factors, including rising demand for biologics, increasing R&D expenditures, and the shift toward flexible and scalable manufacturing solutions. Advances in bioprocessing technologies, such as perfusion bioreactors and single-use systems, are enabling contract manufacturers to optimize production efficiency and reduce time-to-market. Pharmaceutical companies are increasingly outsourcing early-stage research and clinical trials to CROs to gain access to specialized expertise in pharmacokinetics, toxicology, and regulatory compliance. The expanding pipeline of biosimilars and orphan drugs is also driving demand for contract services, as smaller biotech firms seek cost-effective and compliant production solutions. Additionally, the biopharmaceutical industry’s shift toward decentralized clinical trials and real-world data analytics is fostering partnerships with CROs equipped with digital health capabilities. As companies prioritize speed, agility, and cost efficiency, the demand for integrated CMO and CRO solutions will continue to rise, shaping the future of biopharmaceutical innovation and commercialization.

SCOPE OF STUDY:

The report analyzes the Biopharmaceutical CMO and CRO market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product Type (Biologics Type, Biosimilars Type); Source Type (Mammalian Source, Non-Mammalian Source); Service Type (Contract Manufacturing Services, Process Development Services, Fill and Finish Operations, Analytical and QC Studies, Contract Manufacturing Services)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

• AbbVie Inc.
• Baxter International Inc.
• Binex Co., Ltd.
• Biothrive Sciences
• Boehringer Ingelheim GmbH
• Catalent, Inc.
• Charles River Laboratories International, Inc.
• Cummins, Inc.
• Eurofins Scientific SE
• Evotec SE
• FujiFilm Diosynth Biotechnologies U.S.A., Inc.
• ICON plc
• Jrs Pharma GmbH Co. KG
• KBI Biopharma
• Kemwell Biopharma Pvt., Ltd.
• Lonza Group Ltd.
• PAREXEL International Corporation
• ProBioGen AG
• Rentschler Biopharma SE
• Samsung BioLogics Co., Ltd.
• Sartorius AG
• Sterling Pharma Solutions
• Syneos Health
• Thermo Fisher Scientific, Inc.
• Toyobo Co., Ltd.
• WuXi AppTec Co., Ltd.
• WuXi Biologics

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.